Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15531972 | 0.88 | ALDH1A1 (0.56) | FGFR1L3MBTL1ALDH1A1HTTHCAR3 | |
| SCHEMBL31304613 | 0.88 | ALDH1A1 (0.56) | FGFR1L3MBTL1ALDH1A1HTTHCAR3 | |
| SCHEMBL19911387 | 0.86 | FGFR1 (0.51) | FGFR1L3MBTL1ALDH1A1HTTHPGD | |
| SCHEMBL2847737 | 0.84 | MEN1 (0.59) | FGFR1L3MBTL1ALDH1A1HTTHPGD | |
| SCHEMBL1489409 | 0.80 | L3MBTL1 (0.66) | FGFR1L3MBTL1ALDH1A1HTTHPGD | |
| SCHEMBL2292930 | 0.79 | FGFR1 (0.44) | FGFR1L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL23042381 | 0.78 | L3MBTL1 (0.37) | FGFR1L3MBTL1ALDH1A1HTTHCAR3 | |
| SCHEMBL19911374 | 0.77 | FGFR1 (0.57) | FGFR1L3MBTL1ALDH1A1HTTHPGD | |
| SCHEMBL8425553 | 0.76 | FGFR1 (0.60) | FGFR1L3MBTL1ALDH1A1HTTHPGD | |
| SCHEMBL8337275 | 0.76 | FGFR1 (0.60) | FGFR1L3MBTL1ALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1521/4885L3MBTL1 437/4885ALDH1A1 938/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1596/4885L3MBTL1 414/4885ALDH1A1 923/4885 |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | FGFR1 1952/4885L3MBTL1 4217/4885ALDH1A1 2469/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | FGFR1 1437/4885L3MBTL1 351/4885ALDH1A1 1022/4885 |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | FGFR1 1952/4885L3MBTL1 4217/4885ALDH1A1 2469/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | FGFR1 1521/4885L3MBTL1 437/4885ALDH1A1 938/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | FGFR1 1543/4885L3MBTL1 2127/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.